Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-06-2010 | Original Paper

Expression of IL-13Rα2 in liver cancer cells and its effect on targeted therapy of liver cancer

Authors: Lingling Hou, Juan Du, Jianwei Wang, Yanfeng Liu, Weimin Sun, Yanpeng Zheng, Lishu Zhang, Honggang Hu, Xinxian Dai, Weijun Guan, Yuehui Ma, Tao Hong

Published in: Journal of Cancer Research and Clinical Oncology | Issue 6/2010

Abstract

Purpose

Liver cancer is the third leading cause of cancer-related deaths globally. The number of liver cancers diagnosed in the world is increasing at an alarming rate. It is of great significance to find the new targets of the tumor cells and specific medicine. This research investigated the expression of interleukin-13 receptor α2 (IL-13Rα2) in different liver cancer cell lines and liver cancer tissues, and assessed the cytotoxin DT389-hIL13-13E13K (IL-13 and diphtheria toxin fusion protein) targeted killing effect on liver cancer cells. Based on study above, we further analyzed the function of IL-13Rα2 on the targeted liver cancer therapy. The results will provide a novel strategy and an alternative way for liver cancer therapy.

Methods

The expression of IL-13Rα2 in different liver cancer cell lines and tissues were analyzed by RT-PCR and immunohistochemistry. Cytotoxicity assay of DT389-hIL13-13E13K was performed in eight different concentrations in liver cancer cell lines in vitro. At the same time, siRNA-mediated knockdown was introduced to assess the role of IL-13Rα2 in liver cancer therapy.

Results

Two out of four tested liver cancer cell lines and 27 out of 33 (81.82%) liver tissues expressed the IL-13Rα2. The fusion protein DT₃₈₉-hIL13-13E13K showed a moderate cytotoxicity to the cancer cell line BEL-7402 in vitro, which 50% inhibition (IC₅₀) concentration occurred at 1.4 × 10⁻⁵M. Besides, the sensitivity to fusion protein DT₃₈₉-hIL13-13E13K was decreased in siRNA-transfected liver cells compared with control ones. These results suggest that IL-13Rα2 chain is a specific target for IL-13-directed fusion protein.

Conclusions

We reported the expression of IL-13Rα2 in liver cancer cell lines and tissues as well as investigated the cytotoxin (DT389-hIL13-13E13K) targeted killing efficiency of liver cancer cells and potential role of IL-13Rα2 in the cancer treatment.

Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, O’Hara RM Jr, Beier DR, Turner KJ, Wood CR, Collins M (1998) The murine IL-13 receptor a2: molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J Immunol 161:2317–2324PubMed

Du J, Zheng YP, Sun W, Hu HG, Hou LL, Hong T (2008) Targeted killing effect of IL-13 diphtheria toxin fusion protein and DT389-hIL13-13E13K. J Med Res 37(10):31–36

Fluckiger AC, Brière F, Zurawski G, Bridon JM, Banchereau J (1994) IL-13 has only a subset of IL-4-like activities on B chronic lymphocytic leukaemia cells. Immunology 83(3):397–403PubMed

Forner A, Hessheimer AJ, Isabel Real M, Bruix J (2006) Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 60:89–98CrossRefPubMed

Greten TF, Papendorf F, Bleck JS, Kirchhoff T, Wohlberedt T, Kubicka S, Klempnauer J, Galanski M, Manns MP (2005) Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 92(10):1862–1868CrossRefPubMed

Husain SR, Puri RK (2000) Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi’s sarcoma xenograft. Blood 95(11):3506–3513PubMed

Jiang J, Nilsson-Ehle P, Xu N (2006) Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis 5:4CrossRefPubMed

Joshi BH, Plautz GE, Puri RK (2000) Interleukin-13 Receptor α Chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 60(5):1168–1172PubMed

Kawakami K, Kawakami M, Sony PJ, Husain SR, Puri RK (2001) In vivo overexpression of IL-13 receptor α2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J Exp Med 194(12):1743–1754CrossRefPubMed

Kawakami M, Kawakami K, Kasperbauer JL, Hinkley LL, Tsukuda M, Strome SE, Puri RK (2003) Interleukin-13 receptor α2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res 9(17):6381–6388PubMed

Kawakami K, Kawakami M, Puri RK (2004a) Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease. Mol Cancer Ther 3(2):137–147PubMed

Kawakami M, Kawakami K, Takahashi S, Abe M, Puri RK (2004b) Analysis of interleukin-13 receptor α2 expression in human pediatric brain tumors. Cancer 101(5):1036–1042CrossRefPubMed

Kawakami K, Kioi M, Liu Q, Kawakami M, Puri RK (2005) Evidence that IL-13Rα2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy. J Immunother 28(3):193–202CrossRefPubMed

Kioi M, Kawakami K, Puri RK (2004) Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and pseudomonas exotoxin. Clin Cancer Res 10:6231–6238CrossRefPubMed

Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK (2006) Interleukin-13 receptor α2 China: a potential biomarker and molecular target for ovarian cancer therapy. Cancer 107(6):1407–1418CrossRefPubMed

Kioi M, Shimamura T, Nakashima H, Hirota M, Tohnai I, Husain SR, Puri RK (2009) IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma. Int J Cancer 124(6):1440–1448CrossRefPubMed

Kunwar S, Chang SM, Prados MD, Berger MS, Sampson JH, Croteau D, Sherman JW, Grahn AY, Shu VS, Dul JL, Husain SR, Joshi BH (2006) Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 20(4):E15PubMed

Li C, Hall WA, Jin N, Todhunter DA, Panoskaltsis-Mortari A, Vallera DA (2002) Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng 15(5):419–427CrossRefPubMed

Parkin DM, Bray F, Ferlay J, Pisani P (2002) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108CrossRef

Shimamura T, Fujisawa T, Husain SR, Kioi M, Nakajima A, Puri RK (2008) Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. J Immunol 181:4656–4665PubMed

Vogelbaum MA, Sampson JH, Kunwar S, Chang SM, Shaffrey M, Asher AL, Lang FF, Croteau D, Parker K, Grahn AY, Sherman JW, Husain SR, Puri RK (2007) Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase I study of final safety results. Neurosurgery 61(5):1031–1038CrossRefPubMed

Title: Expression of IL-13Rα2 in liver cancer cells and its effect on targeted therapy of liver cancer
Authors: Lingling Hou
Juan Du
Jianwei Wang
Yanfeng Liu
Weimin Sun
Yanpeng Zheng
Lishu Zhang
Honggang Hu
Xinxian Dai
Weijun Guan
Yuehui Ma
Tao Hong
Publication date: 01-06-2010
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 6/2010
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-009-0724-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2010

Potential therapeutic strategy for oral squamous cell carcinoma by ErbB3-binding protein 1 gene transfer

Transformation potential of bone marrow stromal cells into undifferentiated high-grade pleomorphic sarcoma

Promoter hypermethylation in tumour suppressor genes and response to interleukin-2 treatment in bladder cancer: a pilot study

Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues

Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-κB

Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials